FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

ペプチドライブラリー

Triptorelin

Trelstar / Decapeptyl / GnRH agonist

Sexual Health

Triptorelin is a synthetic GnRH agonist (decapeptide analog) that is approximately 100 times more potent than native GnRH, used primarily for sustained suppression of the reproductive axis. It is FDA-approved as Trelstar for the treatment of advanced prostate cancer through chemical castration via continuous GnRH receptor stimulation. In research and clinical contexts, it is also used in post-cycle therapy (PCT) protocols to restart the hypothalamic-pituitary-gonadal axis after anabolic steroid use.

作用機序

Potent GnRH agonist with greatly enhanced receptor binding affinity. Initial administration causes a flare of LH/FSH and testosterone. Continuous administration leads to profound suppression of the HPG axis via pituitary GnRH receptor downregulation.

研究プロトコル

研究目的のみで使用。医療アドバイスではありません。

Research protocols use 50-100mcg as a single dose for hormonal reset. Depot formulations (3.75mg monthly, 11.25mg quarterly, 22.5mg semi-annual) used for sustained suppression. Anti-suppressive protocols use micro-dosing.

研究ノート

Clinical Research Status

Triptorelin holds FDA approval for advanced prostate cancer (Trelstar, in depot formulations of 1-month, 3-month, and 6-month durations) and is approved in Europe for additional indications including endometriosis and precocious puberty. Research has explored single-dose triptorelin (100 mcg) for HPG axis recovery following androgen-induced hypogonadism. The European Medicines Agency also recognizes its use in assisted reproduction protocols for ovulation triggering.

Key Published Findings

A landmark 2010 study (Mourelatos et al.) demonstrated that a single 100 mcg injection of triptorelin could restore gonadotropin levels in men with anabolic steroid-induced hypogonadism within 1-2 weeks. In prostate cancer, depot formulations reduce testosterone to castrate levels (<50 ng/dL) within 2-4 weeks after an initial transient surge. Clinical trials confirm sustained efficacy for testosterone suppression over 6-12 month treatment periods.

Safety Profile

The initial GnRH agonist flare (temporary testosterone increase in the first 1-2 weeks) can exacerbate prostate cancer symptoms and typically requires concurrent anti-androgen coverage. Long-term use causes expected effects of hypogonadism: hot flashes, decreased libido, bone density loss, and metabolic changes. In PCT use, the single low-dose protocol (100 mcg) has minimal reported adverse effects due to the brief exposure duration.

Comparison to Related Compounds

Compared to other GnRH agonists (leuprolide, goserelin), triptorelin has similar efficacy for testosterone suppression but differs in formulation options and pharmacokinetics. For PCT purposes, triptorelin's single-dose protocol contrasts with the multi-week SERM-based approaches using clomiphene or tamoxifen. Unlike gonadorelin which stimulates at pulsatile doses, triptorelin's continuous receptor activation leads to desensitization and suppression after the initial stimulatory phase.

Community Observations

In PCT contexts, the single 100 mcg triptorelin injection protocol has gained popularity as a rapid HPG axis restart option, though evidence remains limited to small studies. Practitioners caution that doses above 100 mcg risk prolonged suppression rather than recovery, making precise dosing critical. Most PCT experts recommend combining triptorelin with SERMs rather than using it as a standalone restart agent for optimal recovery outcomes.

半減期

~3-5 hours (daily form); 28 days (depot)

再構成

Sterile water for injection

保存

乾燥粉末

Refrigerate 2-8C.

再溶解

Use immediately after reconstitution for depot forms.

米国法的状況

FDA-approved (Rx only)

また知られる名前

TrelstarDecapeptylGnRH agonist

よくある質問

Triptorelinとは何ですか?

Triptorelin is a synthetic GnRH agonist (decapeptide analog) that is approximately 100 times more potent than native GnRH, used primarily for sustained suppression of the reproductive axis. It is FDA-approved as Trelstar for the treatment of advanced prostate cancer through chemical castration via continuous GnRH receptor stimulation. In research and clinical contexts, it is also used in post-cycle therapy (PCT) protocols to restart the hypothalamic-pituitary-gonadal axis after anabolic steroid use.

Triptorelinはどのように作用しますか?

Potent GnRH agonist with greatly enhanced receptor binding affinity. Initial administration causes a flare of LH/FSH and testosterone. Continuous administration leads to profound suppression of the HPG axis via pituitary GnRH receptor downregulation.

Triptorelinの米国での規制状況は?

FDA-approved (Rx only)

Triptorelinの半減期は?

~3-5 hours (daily form); 28 days (depot)

Triptorelinの別名は?

Trelstar, Decapeptyl, GnRH agonist

ペプチドコンタクトは、研究目的のみのための要約情報を提供しています。私たちはベンダーの文書をホスト、配布、または推奨していません。すべての分析証明書、GMP認定証明書、およびベンダーコミュニケーションは、購入者によって直接要求され、確認される必要があります。このプラットフォーム上の何らかの情報は法的、医学的、または専門的なアドバイスを構成していません。ユーザーは、適切な法律、州法、および連邦法に準拠するためにベンダー資格を検証し、購入前に遵守することに全責任を持つ必要があります。このプラットフォームを使用することで、完全な個人的責任を承認することになります。

完全な免責事項を読む